A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the University of Michigan have ...

Medtronic plans to launch the system across select clinical and academic centres in the country starting this year.

Pancreatic cancer is one of the most aggressive cancers and has one of the lowest survival rates-only 10% after five years.